← All trials
NCT00947843
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2013
- Primary completion
- Oct 1, 2016
- Completion date
- Oct 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 306
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Seoul National UniversityLead sponsor
- Catholic University of KoreaStudy director
- Ajou UniversityStudy director
- Seoul National UniversityStudy director
- Kyung Hee UniversityStudy director
- Korea UniversityStudy director
- Jeju National UniversityStudy director
- Chong Kun Dang PharmaceuticalCollaborator
- Seoul National UniversityReponsible party - principal investigator
- Dong-A PharmaceuticalStudy director
- Gyeongsang UniversityStudy director
- Hallym UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.